Kenneth Rhodes

Affiliations: 
1992 Anatomy and Neurobiology Boston University, Boston, MA, United States 
Google:
"Kenneth Rhodes"
Mean distance: 14.67
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Sevigny J, Chiao P, Bussière T, et al. (2016) The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 537: 50-6
Brennan MS, Patel H, Allaire N, et al. (2016) Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms. Antioxidants & Redox Signaling
Scannevin RH, Chollate S, Brennan MS, et al. (2015) BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease. Neuropharmacology
Brennan MS, Matos MF, Li B, et al. (2015) Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro. Plos One. 10: e0120254
Atack JR, Shook BC, Rassnick S, et al. (2014) JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease. Acs Chemical Neuroscience. 5: 1005-19
Alfonso S, Kessels HW, Banos CC, et al. (2014) Synapto-depressive effects of amyloid beta require PICK1. The European Journal of Neuroscience. 39: 1225-33
Shook BC, Chakravarty D, Barbay JK, et al. (2013) Substituted thieno[2,3-d]pyrimidines as adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 23: 2688-91
Scannevin RH, Chollate S, Jung MY, et al. (2012) Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. The Journal of Pharmacology and Experimental Therapeutics. 341: 274-84
Shook BC, Rassnick S, Wallace N, et al. (2012) Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease. Journal of Medicinal Chemistry. 55: 1402-17
Peng H, Talreja T, Xin Z, et al. (2011) Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator. Acs Medicinal Chemistry Letters. 2: 786-91
See more...